Closely-held Halia Therapeutics is developing a broad pipeline of novel therapies that are essential mediators of immune cell signaling with the potential to improve the lives of patients with inflammatory disorders and...

Closely-held ImmunoBrain Checkpoint, with its R&D team in Israel, is pursuing a unique approach that targets the peripheral immune system, rather than directly targeting the brain in patients suffering from Alzheimer’s...

Monogram Orthopedics (NASDAQ:MGRM) is working to advance the standard of care with its next-generation robot and 3D-printed implants that match a patient's precise anatomy, decreasing the number of incisions and bone...

Closely-held Cantex Pharmaceuticals has an extensive Phase 2 program underway with its lead drug candidate, azeliragon, in breast cancer, pancreatic cancer, brain metastasis and glioblastoma, well as in prevention of...

HDT Bio is developing messenger RNA vaccines addressing diverse indications in infectious diseases and oncology, and is utilizing regional partnerships for manufacturing, clinical development and commercialization.

Peptilogics is working to change the treatment paradigm of periprosthetic joint infection (PJI), a serious condition that can result from joint replacement surgery. The company is preparing for a registrational clinical...

Closely-held KeifeRx is developing optimized, low dose, oral tyrosine kinase inhibitors (TKIs) for the treatment of multiple neurodegenerative and immune diseases.